Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Debt Repayments (2016 - 2019)

Fate Therapeutics (FATE) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $14.0 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Long-Term Debt Repayments changed N/A year-over-year to $14.0 million, compared with a TTM value of $22.8 million through Dec 2019, changed N/A, and an annual FY2019 reading of $15.0 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $14.0 million for Q4 2019 at Fate Therapeutics, up from $6.7 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $14.0 million in Q4 2019 and bottomed at -$389000.0 in Q3 2015.
  • Average Long-Term Debt Repayments over 4 years is $3.3 million, with a median of $2.0 million recorded in 2016.
  • The sharpest move saw Long-Term Debt Repayments soared 598.2% in 2016, then grew 7.37% in 2017.
  • Year by year, Long-Term Debt Repayments stood at $935000.0 in 2015, then skyrocketed by 111.23% to $2.0 million in 2016, then soared by 239.7% to $6.7 million in 2017, then skyrocketed by 108.67% to $14.0 million in 2019.
  • Business Quant data shows Long-Term Debt Repayments for FATE at $14.0 million in Q4 2019, $6.7 million in Q3 2017, and $2.0 million in Q2 2017.